Cargando…
Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has sufficient clinical efficacy and satisfactory safety in ALK-positive non-small cell lung cancer (NSCLC) patients with or without brain metastasis. Alectinib has now become an important drug in the first-line treatme...
Autores principales: | Chen, Hengyi, Lin, Caiyu, Peng, Tao, Hu, Cheng, Lu, Conghua, Li, Li, Wang, Yubo, Han, Rui, Feng, Mingxia, Sun, FenFen, He, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7010683/ https://www.ncbi.nlm.nih.gov/pubmed/32041944 http://dx.doi.org/10.1038/s41419-020-2307-5 |
Ejemplares similares
-
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway
por: Li, Li, et al.
Publicado: (2015) -
Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
por: Chen, Hengyi, et al.
Publicado: (2017) -
Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway
por: Li, Li, et al.
Publicado: (2016) -
Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination
por: Wang, Zhiguo, et al.
Publicado: (2022) -
Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Lin, Caiyu, et al.
Publicado: (2021)